Alachua, Fla.-based AxoGen regenerative medicine company released its second quarter financial results, and saw revenues jump 42.2 percent while net losses more than doubled over the same period last year.
FREE Webinar--coflex: The New MIS Non-Fusion Solution for Spinal Stenosis Approved for Your ASC! Click here to register.
AxoGen's revenue increased from $2 million in 2012's second quarter to $2.9 million. Company executives attributed the gain to an increased number of facilities using AxoGen's products.
The company's net loss jumped from $3.1 million to $6.9 million, due in part to increased interest costs. The company paid $1.8 million in interest added to the note after having paid no interest the year prior.
More Articles on Devices:
Aesculap's Quintex Anterior Cervical Spine Plating System Now Available
SpineVision Names Ken Yamada as US Subsidiary COO
Orthozon Technologies Launches Lumiere Retractor for Minimally Invasive Discectomy